Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $3.40.

IPSC has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 20th. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a report on Monday, November 17th. Leerink Partnrs cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Finally, Zacks Research upgraded shares of Century Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th.

Century Therapeutics Stock Up 9.6%

NASDAQ:IPSC opened at $1.94 on Friday. The firm has a market capitalization of $169.56 million, a P/E ratio of -6.06 and a beta of 1.72. The company has a fifty day moving average of $0.73 and a 200 day moving average of $0.61. Century Therapeutics has a 52 week low of $0.34 and a 52 week high of $1.95.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. As a group, analysts anticipate that Century Therapeutics will post -1.61 EPS for the current year.

Insider Transactions at Century Therapeutics

In other news, CEO Brent Pfeiffenberger bought 52,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average price of $0.58 per share, with a total value of $30,160.00. Following the transaction, the chief executive officer owned 3,322,990 shares of the company’s stock, valued at approximately $1,927,334.20. The trade was a 1.59% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chad Cowan bought 58,060 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $0.85 per share, with a total value of $49,351.00. Following the purchase, the insider owned 1,045,087 shares in the company, valued at $888,323.95. This trade represents a 5.88% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders purchased 145,060 shares of company stock valued at $97,011 and sold 65,987 shares valued at $29,798. 4.37% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Century Therapeutics

A number of institutional investors have recently added to or reduced their stakes in IPSC. Goldman Sachs Group Inc. grew its position in shares of Century Therapeutics by 26.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after buying an additional 38,052 shares during the period. GSA Capital Partners LLP grew its holdings in Century Therapeutics by 29.3% in the third quarter. GSA Capital Partners LLP now owns 603,479 shares of the company’s stock worth $301,000 after purchasing an additional 136,873 shares during the period. Citadel Advisors LLC increased its stake in shares of Century Therapeutics by 64.1% during the third quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after purchasing an additional 140,891 shares in the last quarter. Two Sigma Investments LP increased its stake in shares of Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after purchasing an additional 338,902 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in shares of Century Therapeutics by 483.1% during the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after purchasing an additional 195,573 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.